[Surgical intramyocardial stem cell therapy for chronic ischemic heart failure]

Related Experiment Video

Updated: Jun 11, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Alexander Kaminski1, Peter Donndorf, Christian Klopsch

  • 1Klinik für Herzchirurgie, Universität Rostock, Schillingallee 35, Rostock,Germany. alexander.kaminski@med.uni-rostock.de

Herz
|July 14, 2010
PubMed

Insights

Bone marrow stem cell therapy combined with bypass surgery is safe for chronic ischemic heart disease. This regenerative medicine approach shows a 7.2% increase in left ventricular ejection fraction (LVEF).

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Surgery
  • Stem Cell Therapy

Context:

  • Chronic ischemic heart disease patients worldwide are treated with bone marrow stem cells in clinical and therapeutic trials.
  • Combining stem cell therapy with revascularization procedures like bypass surgery ensures high patient safety.
  • No cardiac complications have been reported following intramyocardial injection of bone marrow-derived stem cells during coronary artery bypass graft (CABG) surgery.

Purpose:

  • To assess the safety and efficacy of bone marrow stem cell therapy in patients with chronic ischemic heart disease.
  • To evaluate the functional benefits of combining stem cell therapy with coronary artery bypass graft surgery.

Summary:

  • Bone marrow stem cell therapy, when administered during CABG surgery, has demonstrated a significant functional advantage.
  • Patients receiving this combined therapy experienced a 7.2% increase in left ventricular ejection fraction (LVEF) compared to control groups.
  • The intramyocardial injection of bone marrow-derived stem cells during CABG surgery has shown a high safety profile.

Impact:

  • Surgical bone marrow stem cell therapy offers a promising functional improvement for chronic ischemic heart disease patients.
  • Further evidence-based assessment through randomized placebo-controlled trials, such as the PERFECT trial, is recommended.
  • This approach represents a potential advancement in cardiac regenerative medicine, improving patient outcomes.

More Related Videos

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice08:03

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

Intramyocardial Cell Delivery: Observations in Murine Hearts08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...